6.19k followers • 18 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Bristol-Myers Squibb Company
Seattle Genetics, Inc.
Exact Sciences Corporation
Blueprint Medicines Corporation
Inovio Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Foundation Medicine, Inc.
INSYS Therapeutics, Inc.
Bristol-Myers (BMY) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
President Donald Trump’s pointed criticism of the World Health Organization triggered a rebuke from the embattled agency.
New York, New York--(Newsfile Corp. - April 10, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio" or the "Company") of the May 12, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi logoIf you invested in Inovio stock or options between February 14, 2020 and ...
NEW YORK, April 10, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such.
A federal judge increased to $1.2 billion the damages that Gilead Sciences Inc must pay to Bristol-Myers Squibb Co in a patent infringement case regarding technology for treating cancer. The judgment was entered against Gilead's Kite Pharma unit on its "counterclaims of non-infringement and invalidity", according to a ruling by U.S. District Judge Philip Gutierrez. A jury in Los Angeles had awarded damages in December after finding that Yescarta, a treatment sold by Kite Pharma, infringed on a patent exclusively licensed by Bristol-Myers' Juno Therapeutics division.
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Inovio on behalf of those who purchased or otherwise acquired Inovio common stock between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”). Important Deadline Reminder: Investors who purchased or otherwise acquired Inovio common stock during the Class Period may, no later than May 12, 2020, seek to be appointed as a lead plaintiff representative of the class.
The enormity of the coronavirus pandemic has forced biopharma companies to step up efforts to expeditiously develop vaccines and treatments for COVID-19. The Frontrunners Moderna Inc (NASDAQ: MRNA), which was the first company to move its coronavirus vaccine candidate to the clinics, said in mid-March that the first participant has been dosed in an NIH-led, Phase 1 study of its mRNA vaccine in the U.S.Inovio Pharmaceuticals Inc (NASDAQ: INO) announced earlier this week that it is initiating a Phase 1 study to test its DNA vaccine for the coronavirus following the FDA's acceptance of Inovio's IND application.Apart from these companies, CanSino Biologics and the Academy of Military Sciences are running Phase 1 trials of their non-replicating vaccine candidate in China.The University of Oxford is testing a chimpanzee adeno vector vaccine candidate in a Phase 1/2 trial in the U.K.Novavax, Inc. (NASDAQ: NVAX) said Wednesday it has identified a vaccine candidate and is planning to initiate human trials in mid-May.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: How The COVID-19 Outbreak Is Benefiting Biotech Investors Pfizer, BioNTech Make Progress Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX), which initially announced a collaboration to develop a COVID-19 vaccine on March 17, released further details on the partnership Thursday. The companies said they are looking to rapidly advance multiple candidates into human clinical testing based on BioNTech's proprietary mRNA vaccine platforms and leveraging Pfizer's expertise in vaccine R&D, regulatory capabilities and a global manufacturing and distribution network.The clinical trials are planned to be conducted across multiple sites in the U.S. and Europe. Pfizer and BioNTech said they expect to start the first clinical trial as early as the end of April, contingent upon the receipt of regulatory clearance. The collaboration agreement calls for Pfizer to pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million.BioNTech also stands to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.Arcturus Targets Summer Start For Human Trials Arcturus Therapeutics Ltd (NASDAQ: ARCT), an mRNA medicines company, said Thursday it plans to initiate human trials of its COVID-19 vaccine candidate -- LUNAR-COV19 -- this summer.The company said under the guidance of the Health Sciences Authority of Singapore, it plans to start the trial, enrolling 76 healthy volunteer adults, with follow-up over several months to evaluate the extent and duration of immune response.LUNAR-COV19 is a potential single-shot, self-replicating mRNA vaccine devoid of any viral material or co-adjuvants, according to Arcturus. The company said the vaccine candidate is being manufactured, with the initial GMP batch to be delivered in June.PFE, ARCT, BNTX Price Action Pfizer shares were up 2.69% at $35.54 at the time of publication Thursday, while BioNTech shares were up 2.58% at $46.11. Arcturus shares were rising 8.28% to $14.90. Related Link: Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall * The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO * The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW ORLEANS, April 08, 2020 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
After her company completed a merger in November, people told Kim Popovits to take six months off before considering anything.
MENLO PARK, Calif., April 08, 2020 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
Amid the ongoing public health crisis, Wall Street is eagerly awaiting any piece of good news. Inovio Pharmaceuticals (INO) just came through.On Monday, the vaccine maker, which is up 150% year-to-date, announced that the Investigational New Drug (IND) application for its experimental COVID-19 vaccine, INO-4800, had been accepted by the FDA. Additionally, management revealed that the first patient in the Phase 1 trial had been dosed with the DNA vaccine candidate.Commenting on the development, H.C. Wainwright analyst Raghuram Selvaraju said, “We note that this constitutes a validating milestone for Inovio’s DNA medicine platform—i.e., to rapidly develop and advance a vaccine into a Phase 1 trial in just ten weeks.” With initial immune responses and safety data expected to be published by late summer 2020, the analyst sees significant potential based on the immune response results witnessed across several animal models.Not to mention a DNA-based approach offers several advantages. The company’s DNA therapies don’t need cold chain logistics and can be stored at room temperature for one year or at 37°C for one week. On top of this, its innovative injection device is both battery-operated and highly portable. This prompted Selvaraju to conclude that INO’s COVID-19 vaccine could be easy to transport and use all over the world.It should also be noted that in the Phase 1 study of its MERS-CoV vaccine, INO-4700, the candidate generated high levels of antibody responses in about 95% of patients and triggered broad-based T cell responses in almost 90% of patients, with the antibody response maintained for 60 weeks after dosing.Selvaraju added, “T cell responses observed in convalescent patients suggest that the vaccine is able to protect against reinfection with the MERS virus. INO-4700 was well-tolerated with no vaccine-associated serious adverse events.”Based on all of the above, Selvaraju stayed with the bulls. Along with a Buy rating, he left the $13 price target as is. Should this target be met, a twelve-month gain of 57% could be in store. (To watch Selvaraju’s track record, click here)Turning now to the rest of the Street, the bulls have it but not by much. With 3 Buys and 2 Holds assigned in the last three months, the word on the Street is that INO is a Moderate Buy. In addition, the $10.25 average price target is less aggressive than Selvaraju’s forecast. However, it still implies that shares could surge 24% in the next twelve months. (See Inovio stock analysis on TipRanks)
Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat at the Needham Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. Eastern Time. The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.
BMS Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo Plus Yervoy Combined with Limited Chemotherapy in First-Line Lung Cancer
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
CEDARHURST, N.Y., April 07, 2020 -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies..
Bristol-Myers Squibb (BMY) closed the most recent trading day at $56.80, moving -1.85% from the previous trading session.
The U.S. reached a grim milestone on Monday, passing 10,000 coronavirus-related deaths, and according to a prominent physician, the nation won’t move beyond the crisis without a vaccine.
Amid a strong stock market rally, Vertex Pharmaceuticals, Amazon.com, Microsoft, Seattle Genetics and Ciena all moved into buy zones Monday.